Federal contract award
HT942523C0005
AWARD OF R&D DHA PHASE II SBIR TO TECHNOLOGY HOLDING FOR PROJECT TITLED DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODY THERAPEUTIC AGAINST KLEBSIELLA PNEUMONIAE INFECTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.1M |
| Current contract value | $1.1M |
| Potential contract value / ceiling | $1.1M |
| Start date | Feb 27, 2023 |
| Current end date | Jul 26, 2025 |
| Potential end date | Jul 26, 2025 |
| Latest award activity | May 14, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 14, 2025 | P00001 | $0 | DHA PHASE II SBIR FOR PROJECT TITLED DEVELOPMENT OF HUMAN MONOCLONAL ANTIBODY THERAPEUTIC AGAINST KLEBSIELLA PNEUMONIAE INFECTION |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.